Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124715224 | 12471522 | 4 | F | 20160529 | 20160714 | 20160616 | 20160722 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201606004574 | ELI LILLY AND CO | 78.36 | YR | M | Y | 63.00000 | KG | 20160721 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124715224 | 12471522 | 1 | PS | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, EACH MORNING | Y | 21427 | 20 | MG | CAPSULE | QD | |||||
| 124715224 | 12471522 | 2 | C | LOXONIN | LOXOPROFEN SODIUM | 1 | Oral | UNK | 0 | TABLET | |||||||||
| 124715224 | 12471522 | 3 | C | LOXONIN | LOXOPROFEN SODIUM | 1 | Oral | 60 MG, BID | 0 | 60 | MG | TABLET | BID | ||||||
| 124715224 | 12471522 | 4 | C | MUCOSTA | REBAMIPIDE | 1 | Oral | 100 MG, BID | 0 | 100 | MG | TABLET | BID | ||||||
| 124715224 | 12471522 | 5 | C | AZILVA | AZILSARTAN KAMEDOXOMIL | 1 | Oral | 20 MG, EACH MORNING | 0 | 20 | MG | TABLET | QD | ||||||
| 124715224 | 12471522 | 6 | C | CALBLOCK | AZELNIDIPINE | 1 | Oral | 16 MG, EACH MORNING | 0 | 16 | MG | TABLET | QD | ||||||
| 124715224 | 12471522 | 7 | C | PURSENNIDE /00571901/ | 2 | Oral | 24 MG, QD | 0 | 24 | MG | TABLET | QD | |||||||
| 124715224 | 12471522 | 8 | C | MAGNESIUM OXIDE. | MAGNESIUM OXIDE | 1 | Oral | 330 MG, QD | 0 | 330 | MG | TABLET | QD | ||||||
| 124715224 | 12471522 | 9 | C | FAMOTIDINE. | FAMOTIDINE | 1 | Oral | 20 MG, QD | 0 | 20 | MG | DISPERSIBLE TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124715224 | 12471522 | 1 | Back pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124715224 | 12471522 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124715224 | 12471522 | Drug-induced liver injury | |
| 124715224 | 12471522 | Intentional product misuse | |
| 124715224 | 12471522 | Off label use | |
| 124715224 | 12471522 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124715224 | 12471522 | 1 | 20160527 | 20160528 | 0 | |
| 124715224 | 12471522 | 2 | 20160526 | 0 | ||
| 124715224 | 12471522 | 3 | 20160529 | 0 | ||
| 124715224 | 12471522 | 4 | 20160529 | 0 |